Nikoletta Fotaki's research and activities are focused on the prediction of drug absorption through the oral and non oral (i.e.inhalation, subcutaneous) route. She is working on the development of in vitro screening tools and associated software for predicting absorption and in vivo performance (in normal populations and in special populations; i.e. paediatrics), on in vitro dissolution/ biorelevant dissolution methods, on dissolution imaging, on formulation development, design and interpretation of bioavailability and bioequivalency studies, on safety of drugs (pharmacokinetics and toxicokinetics), on the appropriate use of animal models for the prediction of absorption, on the reduction/ refinement/ replacement of animal experimentation and on the development of in vitro-in vivo correlations and relations and on Physiologically Based Pharmacokinetic (PBPK) Modeling.

David R. Schoneker is currently an independent consultant and the President and Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries.

With over 43 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.

In November 2009, Dr Liu joined the University of Hertfordshire as a Lecturer in Clinical Pharmaceutics. Her research interests focus on developing patient-centric medicines for children and older adults. She is a co-chair of the Age-Related Medicines Focus Group in Academy of Pharmaceutical Sciences of Great Britain (APSGB), and is involved in the work of European Paediatric Formulation Initiative (EuPFI) and the Patient Centric Medicine (PaCeMe) initiative.

She has published her work in over 25 peer reviewed journal articles and is the Founder and Executive Director of Fluid Pharma Ltd. 

Maxim Puchkov became the CEO of the Center for Innovation in Computer-Aided Pharmaceutics (CINCAP GmbH) in 2007 and in 2010 he joined the group of Prof. Dr. Jörg Huwyler as scientific collaborator.

His scientific interests are focused on massively-parallel computational models for a design of pharmaceutical formulations; discrete element models for design, understanding, and optimization of pharmaceutical processes and unit operations; interactive and process-oriented computer tools and simulators for advanced teaching and training of industrial unit operations.

Sandra Klein is currently professor of biopharmaceutics and pharmaceutical technology. Prof. Klein is a board member of APV, an EuPFI associate and a member of AAPS, CRS, DPhG. Moreover, she is a member of the editorial board of several scientific journals.

Her current research is focused on developing predictive dissolution methods and dosage forms for special patient groups, particularly the paediatric and geriatric population.

David R. Schoneker is currently an independent consultant and the President and Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries.

With over 42 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.

Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She leads her research group “The Raimi-Abraham Group” and is a board member for the Academy of Pharmaceutical Sciences (APS).

Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.

Alvaro Goyanes is the Development Director and lead project researcher at FabRx. Moreover, he is lecturer at USC and UCL and a highly cited researcher by Clarivate Web of Science for the 2nd year in a row!

Alvaro holds a PhD in pharmaceutical technology and was one of the first researchers assessing opportunities of 3D printing using Fused Deposition Modeling (FDM) to manufacture oral dosage forms and medical devices.

Hans Platteeuw started in 2005 Avivia BV, an independent company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products and in guiding the initial finished product development from phase I all the way up to phase III and commercial production.

His specialty is translating lead compounds into pharmaceutical products that can be made cost effectively and put on a shelf in a pharmacy.

Allison Labriola is a Senior Technical Sales Representative for JRS, specializing in Vivacoat. She supports film coatings from a sales and technical perspective throughout North America.

Allison has an extensive background in pharmaceutical coating and tablet formulation thanks to over 15 years of experience working in sales, technical, and manufacturing roles.

Ajaz Hussain is the President of The National Institute for Pharmaecuetical Technology & Education. His background includes decades of experience in industry, US FDA, and in academic research and teaching to include a number of high-level corporate leadership positions.

His career at US FDA spanned 10 years, where he served as the Deputy Director of the Office of Pharmaceutical Science (OPS) in the Center for Drug Evaluation and Research (CDER) and a “peer reviewed” Senior Biomedical Research position in the US Government Service.

Dario Dornbierer studied pharmaceutical sciences at the ETH Zurich and holds a PhD in the field of sleep pharmacology. During his current bio-entrepreneurial PostDoc position at the University Hospital of Psychiatry in Zurich, he investigates the clinical potential of illicit drugs for the treatment of psychiatric disorders, such as GHB and Ayahuasca.

Moreover, he is continuously driving the research on how to optimize psychiatric drug therapies applying cutting-edge pharmaceutical technologies. Dario acts as Co-founder and CSO of Galventa.

Ana Gutierrez has a pharmaceutical engineering degree from the National Polytechnic Institute and a Masters in Pharmaceutical Sciences from the Metropolitan Autonomous University. She gained considerable industrial experience through positions as manufacturing technology scientist at Bristol Myers Squibb in Mexico, where she also held an Assistant Professor position at the Pharmacy School at the Metropolitan Autonomous University.

At Gattefossé Ana is responsible for providing formulation and process development technical support and delivering internal and external training programs for customers and European universities.

Tomas Skrinskas has been at the leading edge of transformative health care technologies including computer assisted surgery, surgical robotics and genetic nanomedicines for over 15 years, 

His career began with research and engineering which provided a strong foundation for the business development and operations roles that followed. Tomas founded Ascension Sciences, a R&D laboratory focused on nanoparticle development for cannabinoid products and therapeutics, in January 2019.

Cross-functional team lead covering aspects of novel product and process development, regulatory strategy, intellectual property, and market assessment. 

Member of the innovation teams responsible for development and regulatory entrée of 3D printed products in multiple medical fields. Over twenty years of experience applying 3D printing technology to pharmaceuticals and medical devices.

Familiar with startup to commercial stage corporate environment, ranging from a few people to over 100. Significant interaction with legal counsel across specialties, including FDA law, patent & trademark law, and contract law.

Pavel Abdulkin is the Chief Commercial Officer at Microcaps AG. He has over 10 years experience in development of nano- and microencapsulation techniques to enable controlled release and targeted delivery applications across pharmaceutical and nutraceutical industries.

At Microcaps Pavel is responsible for development and implementation of the commercial strategy as well as customer outreach and strategic partnerships.

Dr. Tomaž Einfalt is a project leader at the University of Basel. During the last 4 years he has been working on translating exosomal and lipid nanoparticle technologies from bench to bedside. 

His work was featured at the Swiss Innovation Challenge and lead to key industry collaborations looking into translation of inventions into clinical products. 

Krizia holds a PhD in Chemical and Biochemical Engineering from Rutgers University in New Jersey, USA and more than 10 years of experience in the pharmaceutical industry. Her technical approaches include formulation optimization, continuous manufacturing processes for solid oral dosage products, Process Analytical Technology (PAT) and spectroscopy for real-time measurements of critical quality attributes.

Her work extends to global companies including Pfizer, Bristol-Myers Squibb, AstraZeneca and Eli-Lilly. Krizia has published articles and chapters on innovative formulations, new drug delivery methods, process engineering and controls, and the implementation and validation of PAT tools.

Lise Vandevivere is a pharmacist and currently a PhD researcher at Ghent University. She is a member of the Laboratory of Pharmaceutical Technology supervised by Prof. Dr. Chris Vervaet.

Her research is focussing on formulation development using the fully continuous ConsiGma-25 production line.